Results 71 to 80 of about 1,338,841 (294)
Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis [PDF]
, 2007 Objective: To assess the cost effectiveness of primary angioplasty, compared with medical management with thrombolytic drugs, to achieve reperfusion after acute myocardial infarction ( AMI) from the perspective of the UK NHS.
Abrams, Keith +6 more
core +2 more sources
Molecular Oncology, EarlyView.Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard +12 more
wiley +1 more source
Cost of clinical events in health economic evaluations in Germany: a systematic review
Cost Effectiveness and Resource Allocation, 2012 Guidance from the Institute for Quality and Efficiency in Health Care (IQWiG) on cost estimation in cost–benefit assessments in Germany acknowledges the need for standardization of costing methodology.
Scheuringer Monika +3 more
doaj +1 more source
Some reflections on the use of inappropriate comparators in CEA
Cost Effectiveness and Resource Allocation, 2020 Although the choice of the comparator is one of the aspects with a highest effect on the results of cost-effectiveness analyses, it is one of the less debated issues in international methodological guidelines. The inclusion of an inappropriate comparator
José Antonio Sacristán +4 more
doaj +1 more source
Screening for lung cancer: A systematic review of overdiagnosis and its implications
Molecular Oncology, EarlyView.Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz +12 more
wiley +1 more source
Biosimilar medicines and cost-effectiveness
ClinicoEconomics and Outcomes Research, 2011 Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj
Cost Effectiveness and Resource Allocation, 2018 Background Multicriteria decision analysis (MCDA) has the potential to bring more structure and transparency to health technology assessment (HTA). The objective of this paper is to highlight key methodological and practical challenges facing the use of ...
Kevin Marsh +3 more
doaj +1 more source
Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand. [PDF]
, 2006 BACKGROUND: Much emphasis is put on providing evidence to assist policymakers in priority setting and investment decisions. Assessing the cost-effectiveness of interventions is one technique used by policymakers in their decisions around the allocation ...
Tantivess, Sripen, Walt, Gill
core +2 more sources
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source